Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Vascular Diseases D014652 16 associated lipids
Pregnancy Complications, Hematologic D011250 11 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Alcoholic Intoxication D000435 15 associated lipids
Ascites D001201 25 associated lipids
Albuminuria D000419 18 associated lipids
Anemia D000740 21 associated lipids
Chediak-Higashi Syndrome D002609 4 associated lipids
Heart Valve Diseases D006349 4 associated lipids
Infant, Premature, Diseases D007235 7 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Sambu N et al. Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study. 2011 Heart pmid:21795297
Spectre G et al. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. 2011 Thromb. Haemost. pmid:21800009
Hoh CM et al. Evaluation of effects of low-dose aspirin administration on urinary thromboxane metabolites in healthy dogs. 2011 Am. J. Vet. Res. pmid:21801060
Dalli E et al. Effects of hawthorn (Crataegus laevigata) on platelet aggregation in healthy volunteers. 2011 Thromb. Res. pmid:21737127
Gao F et al. Effect of polymorphism and type II diabetes on aspirin resistance in patients with unstable coronary artery disease. 2011 Chin. Med. J. pmid:21740787
Lukasik M et al. Aspirin treatment influences platelet-related inflammatory biomarkers in healthy individuals but not in acute stroke patients. 2011 Thromb. Res. pmid:21788065
Shen L et al. In vivo oxidation, platelet activation and simultaneous occurrence of natural immunity in atherosclerosis-prone mice. 2011 Isr. Med. Assoc. J. pmid:21845968
Mattiello T et al. Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting. 2011 J. Am. Coll. Cardiol. pmid:21816313
Puccetti L et al. Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. 2011 Atherosclerosis pmid:21056418
Bauer J et al. Arzanol, a prenylated heterodimeric phloroglucinyl pyrone, inhibits eicosanoid biosynthesis and exhibits anti-inflammatory efficacy in vivo. 2011 Biochem. Pharmacol. pmid:20933508
Oates JC et al. Selective cyclooxygenase-2 inhibitor suppresses renal thromboxane production but not proliferative lesions in the MRL/lpr murine model of lupus nephritis. 2011 Am. J. Med. Sci. pmid:20924284
Grove EL et al. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. 2011 J. Thromb. Haemost. pmid:20955349
Trostchansky A et al. Nitroarachidonic acid, a novel peroxidase inhibitor of prostaglandin endoperoxide H synthases 1 and 2. 2011 J. Biol. Chem. pmid:21266582
Trefiletti G et al. 1-Phenyl-6,7-dihydroxy-isochroman suppresses lipopolysaccharide-induced pro-inflammatory mediator production in human monocytes. 2011 Br. J. Nutr. pmid:21269535
Gremmel T et al. Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation. 2011 Platelets pmid:21231857
Kuo HL et al. NP-313, 2-acetylamino-3-chloro-1,4-naphthoquinone, a novel antithrombotic agent with dual inhibition of thromboxane A(2) synthesis and calcium entry. 2011 Br. J. Pharmacol. pmid:21232029
Kleinbongard P et al. Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. 2011 Circ. Res. pmid:21183739
Dimitrievska S et al. Low thrombogenicity coating of nonwoven PET fiber structures for vascular grafts. 2011 Macromol Biosci pmid:21259437
Ceprnja M et al. Oxidative stress markers in patients with post-traumatic stress disorder. 2011 Coll Antropol pmid:22397253
Toliopoulos IK et al. Inhibition of platelet aggregation and immunomodulation of NK lymphocytes by administration of ascorbic acid. 2011 Indian J. Exp. Biol. pmid:22403863